These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35512806)

  • 1. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
    Qian Y; Markowitz JS
    Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
    Bansal S; Maharao N; Paine MF; Unadkat JD
    Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
    Qian Y; Wang X; Markowitz JS
    Drug Metab Dispos; 2019 May; 47(5):465-472. PubMed ID: 30833288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
    Bansal S; Paine MF; Unadkat JD
    Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
    Qian Y; Gurley BJ; Markowitz JS
    J Clin Psychopharmacol; 2019; 39(5):462-471. PubMed ID: 31433338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
    Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
    Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
    Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
    Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
    Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
    Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
    Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid-Induced Inhibition of Morphine Glucuronidation and the Potential for In Vivo Drug-Drug Interactions.
    Coates S; Bardhi K; Lazarus P
    Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex.
    Xiao J; Shi J; Thompson BR; Smith DE; Zhang T; Zhu HJ
    J Pharm Sci; 2022 Sep; 111(9):2606-2613. PubMed ID: 35526575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina.
    Fernández N; Cappello MG; Quiroga PN
    Forensic Sci Int; 2023 Aug; 349():111762. PubMed ID: 37392612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects.
    Markowitz JS; De Faria L; Zhang Q; Melchert PW; Frye RF; Klee BO; Qian Y
    Med Cannabis Cannabinoids; 2022; 5(1):199-206. PubMed ID: 36467779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
    Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
    Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
    Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of Δ
    Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
    Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of escalating cannabinoid doses in healthy cats.
    Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
    J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of UDP-Glucuronosyltransferase Enzymes by Major Cannabinoids and Their Metabolites.
    Nasrin S; Watson CJW; Bardhi K; Fort G; Chen G; Lazarus P
    Drug Metab Dispos; 2021 Dec; 49(12):1081-1089. PubMed ID: 34493601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.